123 filings
ARS
2023 FY
BEAM
Beam Therapeutics Inc
19 Apr 24
Annual report to shareholders
4:25pm
DEFA14A
BEAM
Beam Therapeutics Inc
19 Apr 24
Additional proxy soliciting materials
4:20pm
DEF 14A
BEAM
Beam Therapeutics Inc
Definitive proxy
19 Apr 24
4:15pm
S-3ASR
BEAM
Beam Therapeutics Inc
27 Feb 24
Automatic shelf registration
6:10pm
S-8
BEAM
Beam Therapeutics Inc
27 Feb 24
Registration of securities for employees
7:40am
8-K
br0yi9p6tmi8u6v
27 Feb 24
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
6:43am
8-K
i43cl37z990rap69ueu
8 Jan 24
Results of Operations and Financial Condition
6:55am
8-K
tzf0a4
14 Dec 23
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
4:05pm
8-K
wqeap1qyhjwtcya13dr
8 Nov 23
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
7:00am
8-K
t5103v0k
31 Oct 23
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
6:44am
8-K
n0ozl2h9
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
UPLOAD
ihaip7tjulsx2jq
12 Oct 23
Letter from SEC
12:00am
CORRESP
ows1g57931kit 5ei
20 Sep 23
Correspondence with SEC
12:00am
UPLOAD
9xibwkk1 hx2g
22 Aug 23
Letter from SEC
12:00am
CORRESP
up76g n7k
9 Aug 23
Correspondence with SEC
12:00am
8-K
zhgcg0
8 Aug 23
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
7:11am
UPLOAD
lqp8g2rbvujziwawk1
20 Jul 23
Letter from SEC
12:00am